Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Relative performance of nebulizers used in acute care wards

Adam Metcalf, Dirk Von Hollen, Steven P. Cowley, Lois Slator, Lucy E. A. Hardaker
European Respiratory Journal 2020 56: 2756; DOI: 10.1183/13993003.congress-2020.2756
Adam Metcalf
1Respironics Respiratory Drug Delivery (uk) Ltd, a business of Philips Electronics UK Limited, Chichester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adam.mecalf@philips.com
Dirk Von Hollen
2Respironics Inc, a Philips Healthcare company, Murraysville, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven P. Cowley
1Respironics Respiratory Drug Delivery (uk) Ltd, a business of Philips Electronics UK Limited, Chichester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lois Slator
1Respironics Respiratory Drug Delivery (uk) Ltd, a business of Philips Electronics UK Limited, Chichester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy E. A. Hardaker
1Respironics Respiratory Drug Delivery (uk) Ltd, a business of Philips Electronics UK Limited, Chichester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Nebulizers used in acute care wards must be relied upon to rapidly deliver aerosols to patients who may be suffering an asthma attack. Both the respirable delivered dose and the respirable output rate are of significance for the rapid delivery of therapeutic doses to the target sites of action in the lungs. We tested 4 nebulizers used in acute care wards, in vitro, to determine their aerosol delivery performance into simulated adult breathing.

Six of each nebulizer brand (Table 1; SSD -Philips SideStream Disposable, HMM -Hudson Micro Mist, AMF -AirLife Misty Fast, SND-Salter Nebutech Disposable 8960) were tested once for particle size and output. Each nebulizer was tested with salbutamol sulphate (Salamol 5 mg/ 2.5 mL) for particle size (Malvern Spraytec) and separately for delivered dose. Delivered dose was determined using a filter connected to a breathing simulator set to generate a sine wave (Vt=500 mL, f=15 bpm, I:E=1:1). Nebulizers were run until sputter plus 60 s. Salbutamol was quantitated by high performance liquid chromatography.

View this table:
  • View inline
  • View popup
Table 1

Mean nebulizer performance at 8 L/min driving flow (n=6).

There was a wide range in performance, nebuilzers with the shortest nebulization time delivered the lowest respirable delivered doses and lowest respirable output rates. Speed of treatment in acute cae should be assessed using respirable output rate not nebulization time alone.

  • Asthma
  • Bronchodilators

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2756.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2020
Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Relative performance of nebulizers used in acute care wards
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Relative performance of nebulizers used in acute care wards
Adam Metcalf, Dirk Von Hollen, Steven P. Cowley, Lois Slator, Lucy E. A. Hardaker
European Respiratory Journal Sep 2020, 56 (suppl 64) 2756; DOI: 10.1183/13993003.congress-2020.2756

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Relative performance of nebulizers used in acute care wards
Adam Metcalf, Dirk Von Hollen, Steven P. Cowley, Lois Slator, Lucy E. A. Hardaker
European Respiratory Journal Sep 2020, 56 (suppl 64) 2756; DOI: 10.1183/13993003.congress-2020.2756
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Late Breaking Abstract - Enhanced immune activation pathways enriched in patients =70 years with severe COVID-19
  • Evaluation of the relationship between KIM-1 and suPAR level in COVID-19 patients and a different perspective on suPAR
  • POST-COVID-19 LUNG FIBROSIS: STUDY OF 600 CASES IN TERTIARY CARE SETTING IN INDIA
Show more Acute critical care

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society